Overview

An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19

Status:
Active, not recruiting

Trial end date:
2020-08-31

Target enrollment:

Participant gender:

Summary

The observational study will be carried out in two stages. At the first stage, the efficacy and safety of Aprotinin intravenous infusion as add-on therapy to the standard of care will be studied. At the second stage, two groups will be included: the first group will be the inhaled Aprotinin add-on therapy, the second group will be intravenous Aprotinin in combination with Favipiravir.

Phase:

N/A

Details

Lead Sponsor:

Aviron LLC

Treatments:

Aprotinin